CBL
CBL (E3 ubiquitin-protein ligase CBL) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 5 more.
Overview
E3 ubiquitin-protein ligase that acts as a negative regulator of many signalling pathways by mediating ubiquitination of cell surface receptors. Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognises activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signalling.
CIViC holds 8 clinical evidence items and 0 assertions across 9 variants, naming SU11274. Open Targets scores its association with cancer at 0.86 (direct and indirect evidence; datatypes genetic literature 0.76, affected pathway 0.81, literature 0.98, genetic association 0.81, somatic mutation 0.90, animal model 0.61). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Oesophageal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CBL (E3 ubiquitin-protein ligase CBL) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 5 more.
- 1 · What it is
CBL (E3 ubiquitin-protein ligase CBL) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Myeloproliferative neoplasms, Leukaemia, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
E3 ubiquitin-protein ligase that acts as a negative regulator of many signalling pathways by mediating ubiquitination of cell surface receptors.
- 3 · How drugs use it
No product in this corpus aims at CBL yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:1541 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P22681 (protein name, function text, keywords and locations (REST API)); CIViC gene CBL (8 evidence items, 0 assertions, 9 variants; diseases: Lung Non-small Cell Carcinoma, Acute Myeloid Leukaemia, Juvenile Myelomonocytic Leukaemia (GraphQL API, CC0)); Open Targets ENSG00000110395 (association with cancer (MONDO_0004992) 0.86; per-cancer scores at or above 0.5: ovarian cancer 0.56, melanoma 0.58, sarcoma 0.52, acute myeloid leukaemia 0.59, skin cancer 0.58, myeloproliferative neoplasm 0.81 (GraphQL API, CC0)); IntOGen CBL (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
E3 ubiquitin-protein ligase that acts as a negative regulator of many signalling pathways by mediating ubiquitination of cell surface receptors. Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognises activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signalling. Recognises membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation. Ubiquitinates EGFR and SPRY2. Involved in LAG3-mediated inhibition of TCR signalling: following ligand-binding to LAG3, catalyses 'Lys-63'-linked ubiquitination of LAG3, unleashing the LAG3 C-terminus from the membrane, and initiating a signalling that prevents TCR activation. Location: Cytoplasm; Cell membrane; Cell projection, cilium; Golgi apparatus (UniProt). Locus 11q23.3 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.81 with myeloproliferative neoplasm (MONDO_0020076)
- Leukaemia: Open Targets association 0.80 with leukaemia (MONDO_0005059)
- Skin cancer: Open Targets association 0.58 with skin cancer (MONDO_0002898)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Ovarian cancer: Open Targets association 0.56 with ovarian cancer (MONDO_0008170)
- Sarcomas: Open Targets association 0.52 with sarcoma (MONDO_0005089)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 8 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Juvenile Myelomonocytic Leukaemia.
Latest papers
topQuery for this target: (TITLE:"CBL" OR ABSTRACT:"CBL" OR TITLE:"Cbl proto-oncogene" OR ABSTRACT:"Cbl proto-oncogene" OR TITLE:"E3 ubiquitin-protein ligase CBL" OR ABSTRACT:"E3 ubiquitin-protein ligase CBL" OR TITLE:"RNF55" OR ABSTRACT:"RNF55" OR TITLE:"c-Cbl" OR ABSTRACT:"c-Cbl" OR TITLE:"CBL2" OR ABSTRACT:"CBL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CBL, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZRSR2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetGATA1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetCSF2RB
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetERCC4
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetRPL5
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), Acute myeloid leukaemia.
- TargetFANCA
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.
- TargetRAD21
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, IntOGen.
- TargetSRSF2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Skin cancer (all types), CIViC.